# Cannabinoid Effects on Substance Use Disorders: Evidence and Insights

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabinoid-effects-substance-use-disorders-review/
> **Published:** 2026-08-11T18:36:27-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:00:56-04:00
> **Clinical Summary:** Explore cannabinoid effects substance use disorders with a tier-weighted review of 97 studies showing short-term benefits but limited sustained outcomes.

---

CED Clinical Relevance #82 Clinical Evidence Update A PROSPERO-registered, tier-weighted systematic review of 97 human studies (41,954 participants) across five substance use disorders, published 2026 in European Psychiatry, found that cannabinoids show short-term symptom benefit concentrated in weaker study designs, while more rigorous evidence on sustained treatment outcomes (retention, relapse, abstinence) mostly showed no significant effect. Its breadth, pre-registration, design-matched risk-of-bias tools, and clinically important short-term-versus-sustained distinction place it above the newsjack threshold, though it is a narrative synthesis rather than a meta-analysis.

Clinical Insight | CED Clinic
Patients in [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and the clinicians who treat them frequently ask whether cannabis or cannabinoid medications can help with cravings, withdrawal, or long-term recovery from opioid, alcohol, cocaine, tobacco, or methamphetamine use disorders. A newly published tier-weighted systematic review pooled 97 human studies covering 41,954 participants to answer that question directly, separating short-term symptom relief from the sustained outcomes that actually define successful [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/): staying in treatment, avoiding relapse, and achieving abstinence. The review’s central finding is a distinction worth sitting with: cannabinoids showed real signal for short-term symptoms, but that signal came disproportionately from weaker study designs, while the more rigorous evidence on sustained outcomes mostly showed no significant effect.

Substance Use Disorders[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)CannabinoidsSystematic ReviewOpioid Use Disorder

Audience
Patients in treatment for substance use disorders, [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) clinicians, primary care physicians fielding questions about cannabinoids as an adjunct to SUD treatment, and cannabis clinicians counseling patients with co-occurring substance use history

Primary Topic
A tier-weighted systematic review of 97 human studies (41,954 participants) examining whether cannabinoid exposure improves outcomes across opioid, alcohol, cocaine, tobacco, and methamphetamine use disorders, published in European Psychiatry in 2026

Source
[Read the study in European Psychiatry](https://doi.org/10.1192/j.eurpsy.2026.12236)

Table of Contents

- [Cannabinoids for Substance Use Disorders: What 97 Studies Show and Do Not Show](#Cannabinoids_for_Substance_Use_Disorders_What_97_Studies_Show_and_Do_Not_Show)
- [How to Read a Review That Splits Short-Term Relief From Long-Term Outcomes](#How_to_Read_a_Review_That_Splits_Short-Term_Relief_From_Long-Term_Outcomes)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame)
- [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Short-Term Relief Is Not the Same as Long-Term Success](#Short-Term_Relief_Is_Not_the_Same_as_Long-Term_Success)
- [A Useful Map of Where the Evidence Actually Stands](#A_Useful_Map_of_Where_the_Evidence_Actually_Stands)
- [The Headline Percentage Undersells the Weakness Beneath It](#The_Headline_Percentage_Undersells_the_Weakness_Beneath_It)
- [A Fair Answer to a Common Patient Question](#A_Fair_Answer_to_a_Common_Patient_Question)
- [A Narrative Synthesis, Not a Meta-Analysis](#A_Narrative_Synthesis_Not_a_Meta-Analysis)
- [Symptom Relief Still Has Value, Even Without Proven Cure](#Symptom_Relief_Still_Has_Value_Even_Without_Proven_Cure)
- [Precision Protects Patients in Recovery](#Precision_Protects_Patients_in_Recovery)
- [A Clear Case for the Trials That Have Not Been Run](#A_Clear_Case_for_the_Trials_That_Have_Not_Been_Run)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## Cannabinoids for Substance Use Disorders: What 97 Studies Show and Do Not Show

A tier-weighted systematic review pooled 97 studies and 41,954 participants to ask whether cannabinoids help treat substance use disorders. Short-term symptoms like craving, withdrawal, and consumption showed frequent benefit, but that benefit came mostly from weaker study designs. The more rigorous evidence on sustained outcomes, treatment retention, relapse, and abstinence, mostly showed no significant effect, especially for opioid use disorder.

What This Study Teaches Us
This review shows why the question ‘does cannabis help treat addiction’ needs to be split into two separate questions: does it ease short-term symptoms like craving and withdrawal, and does it improve the sustained outcomes that define successful treatment. The tier-weighted design, which discounts findings from weaker study types, makes clear that most of the encouraging short-term results come from the least rigorous evidence, while the best-designed studies on long-term outcomes mostly found no effect.

Why This Matters
[Addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) has few adjunctive treatment options with strong evidence for most substance use disorders, and patients frequently ask whether cannabis products could help with cravings or withdrawal during treatment. A comprehensive review of the full 50-year human evidence base, using formal risk-of-bias tools for every study type and pre-registered methodology, gives clinicians a rare opportunity to see how the whole picture holds up once it is weighted by study quality rather than counted at face value.

Study Snapshot

Study Type
Tier-weighted systematic review (Synthesis Without Meta-analysis / SWiM guidance), PROSPERO-registered (CRD420251151193)

Population
97 human studies, 41,954 total participants, spanning opioid, alcohol, cocaine, tobacco, and methamphetamine use disorders

Search Window
PubMed and Embase, 1975 to 2025

Risk-of-Bias Tools
RoB 2 for randomized controlled trials, ROBINS-I for cohort studies, JBI checklists for cross-sectional, case, and qualitative designs

Endpoints Assessed
Treatment retention, relapse, abstinence, craving, withdrawal severity, and consumption

Weighting Scheme
Design-based weighting from randomized controlled trial (1.00) down to qualitative evidence (0.25)

Endpoint Instances
195 endpoint instances across the 97 studies: 89 Beneficial (45.6%), 80 No Significant Effect (41.0%), 12 Mixed/Partial (6.2%), 14 Harmful/Inferior (7.2%)

Where Benefit Concentrated
76.4% of Beneficial findings were short-term symptom targets (craving, withdrawal, consumption), not sustained outcomes

Design Quality Behind Benefit
Beneficial findings for craving (81.5%), withdrawal severity (85.7%), and consumption (80.0%) came overwhelmingly from weaker study designs

Sustained Outcomes
Predominantly No Significant Effect, most pronounced in opioid use disorder

Authors’ Conclusion
Cannabinoids confer short-horizon symptomatic benefits but do not demonstrate efficacy for sustained abstinence, relapse prevention, or treatment retention; findings are strongest, though still not proof of efficacy, for opioid use disorder and preliminary for other disorders. Adequately powered adjunctive randomized trials with biochemically verified endpoints are needed.

Journal
European Psychiatry

Published
2026, volume 69, issue 1, e73 (first published online July 17, 2026)

DOI
10.1192/j.eurpsy.2026.12236

PMID
42466639

Affiliations
University of Edinburgh; University of Malta Faculty of Medicine and Surgery

Clinical Bottom Line
A tier-weighted review of 97 studies and nearly 42,000 participants found that cannabinoids show a real short-term symptom benefit for craving, withdrawal, and consumption, but that benefit is concentrated in weaker study designs, while the more rigorous evidence on sustained outcomes like relapse, abstinence, and treatment retention mostly showed no significant effect, most clearly for opioid use disorder.

What the Review Analyzed

Researchers searched PubMed and Embase from 1975 through 2025 for human studies evaluating cannabinoid exposure in relation to substance use disorder outcomes across opioid, alcohol, cocaine, tobacco, and methamphetamine use disorders. Two reviewers independently screened and extracted data from every included study.

Six endpoints were prespecified and mapped onto each target disorder: treatment retention, relapse, abstinence, craving, withdrawal severity, and consumption. Every study’s risk of bias was assessed with a design-matched tool: RoB 2 for randomized controlled trials, ROBINS-I for cohort studies, and JBI checklists for cross-sectional, case, and qualitative designs.

A Weighting Scheme That Discounts Weak Evidence

Rather than simply counting how many studies reported a benefit, the review applied a design-based weighting scheme that assigned randomized controlled trials the highest weight (1.00) and qualitative studies the lowest (0.25), following Synthesis Without Meta-analysis (SWiM) guidance. This tier-weighted approach is what lets the findings distinguish a real effect from a signal produced mostly by weaker study types.

Ninety-seven studies covering 41,954 participants contributed 195 separate endpoint instances to the final synthesis, pre-registered on PROSPERO before the review began.

Short-Term Symptoms Showed the Most Benefit

Of the 195 endpoint instances, 89 (45.6%) were classified as Beneficial, 80 (41.0%) as No Significant Effect, 12 (6.2%) as Mixed or Partial, and 14 (7.2%) as Harmful or Inferior.

The large majority of Beneficial findings, 76.4%, were for short-term symptom targets such as craving, withdrawal, and consumption rather than for the sustained outcomes that define successful [addiction treatment](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/).

The Benefit Came Mostly From Weaker Studies

When the review broke down which study designs were driving the Beneficial findings for short-term symptoms, the pattern was stark: 81.5% of Beneficial craving findings, 85.7% of Beneficial withdrawal severity findings, and 80.0% of Beneficial consumption findings came from weaker study designs, not from randomized controlled trials.

This is exactly the pattern a tier-weighted review is built to catch. A raw vote-count of how many studies found a benefit would have overstated the strength of this evidence considerably.

Sustained Outcomes Told a Different Story

For the outcomes that matter most in real-world addiction treatment, treatment retention, relapse, and abstinence, results were predominantly classified as No Significant Effect. This pattern was most pronounced in opioid use disorder, where the evidence base was largest and most rigorous.

The authors note that findings for opioid use disorder are the strongest in the review, meaning the most rigorously tested, not that cannabinoids were shown to work best there. Evidence for the other four disorders, alcohol, cocaine, tobacco, and methamphetamine use disorders, remains preliminary.

What the Authors Themselves Concluded

The study authors state directly: cannabinoids confer short-horizon symptomatic benefits but do not demonstrate efficacy for sustained abstinence, relapse prevention, or retention, most clearly in opioid use disorder, where evidence is strongest. Findings for other disorders remain preliminary.

They call for adequately powered adjunctive randomized trials with biochemically verified endpoints, rather than self-reported outcomes, as the necessary next step.

How Strong Is This Evidence?
This is one of the more methodologically careful reviews of cannabinoids in addiction treatment to date. It searched 50 years of literature across two major databases, pre-registered its protocol on PROSPERO, used design-matched risk-of-bias tools for every included study type, and applied a formal design-based weighting scheme rather than simply counting studies that reported a positive result. Covering 97 studies and 41,954 participants across five separate substance use disorders gives it real breadth, and the fact that its own methodology surfaced the gap between weak-study optimism and strong-study null results is a sign the synthesis is doing its job rather than papering over inconvenient findings.

Where This Paper Deserves Skepticism
The review’s own tiered weighting is also its most important caution: a substantial share of the encouraging short-term findings, for craving, withdrawal severity, and consumption specifically, came from the weakest tiers of evidence rather than from randomized controlled trials. That does not mean those findings are false, but it does mean they have not yet been confirmed by the kind of rigorous, controlled testing needed to rule out placebo response, expectation effects, and selection bias. The review is also a narrative synthesis rather than a formal meta-analysis, so no pooled effect size or confidence interval is available to quantify how large or reliable any individual benefit actually is. Endpoint classification into categories such as Beneficial, Mixed/Partial, or Harmful/Inferior necessarily involves judgment calls by the reviewers, even when applied systematically. Finally, five very different substance use disorders were combined into a single synthesis, and evidence quality and volume clearly differed across them, with opioid use disorder carrying the largest and most rigorous evidence base while the other four disorders remain comparatively under-studied.

What This Paper Does Not Show
This review does not show that cannabinoids are an effective treatment for any substance use disorder. It does not show that cannabinoids improve treatment retention, relapse prevention, or abstinence, the outcomes that actually define successful addiction treatment, since those sustained outcomes were predominantly null across the pooled evidence. It does not establish a specific effective dose, formulation, or cannabinoid, THC, CBD, or a combination, responsible for any observed short-term symptom benefit, since the review synthesized findings across a wide range of cannabinoid exposures. It also does not, on the basis of the details available here, address whether cannabinoid use during SUD treatment carries risks specific to that population, such as interactions with other addiction medications, since that was outside this review’s six prespecified endpoints.

How This Fits With the Broader Clinical Conversation

This review sits inside a longer-running debate in addiction medicine about whether cannabinoids belong in the treatment toolkit for substance use disorders. Interest has grown alongside broader [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) and a search for adjunctive options for opioid use disorder in particular, given the severity of the ongoing overdose crisis.

What this review adds to that debate is a comprehensive, quality-weighted look at the full evidence base rather than a review of a single drug, single disorder, or single study design. Its central contribution, that short-term symptom benefit and long-term outcome improvement are not the same evidence, and one does not currently support the other, is a distinction worth carrying into any future conversation about cannabinoids as an SUD treatment.

Dr. Caplan’s Take

*I have spent more than 20 years practicing evidence-based [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), and this is the kind of review I want to see more of, not because it delivers a clean yes or no, but because it is honest about the difference between those two answers. A tier-weighted synthesis that actually shows its work, that the encouraging short-term findings on craving and withdrawal come disproportionately from weaker study designs, while the best-designed evidence on relapse, retention, and abstinence mostly shows nothing, is a more useful and more trustworthy result than a simple vote count would have produced.*

*If a patient in addiction treatment asks me whether cannabis or a cannabinoid product will help them stay off opioids, alcohol, or another substance long-term, this review tells me I cannot honestly say yes based on the current evidence. I can say that short-term symptom relief has some support, mostly from weaker studies, and that the rigorous trials we actually need, adequately powered, adjunctive, with biochemically verified outcomes rather than self-report, have not yet been run at the scale this question deserves. That is not a reason to dismiss cannabinoids in addiction care. It is a reason to be precise with patients about what we know and do not yet know, and to keep pushing for the trials that would resolve it.*

What a Careful Reader Should Take Away
A tier-weighted review of 97 studies and 41,954 participants found real short-term symptom benefit for cannabinoids in substance use disorder treatment, concentrated in weaker study designs, while the more rigorous evidence on sustained treatment outcomes, retention, relapse, and abstinence, mostly showed no significant effect, especially for opioid use disorder. This is a call for better trials, not evidence that cannabinoids currently treat addiction.

Evidence Interpretation Guide

## How to Read a Review That Splits Short-Term Relief From Long-Term Outcomes

A review reporting that 45.6% of findings were Beneficial can sound like strong evidence for cannabinoids in addiction treatment at first glance.

Four checks keep this review’s real, more limited contribution in view.

### A Four-Step Reading Frame

**Separate symptom relief from treatment success**Most Beneficial findings were for short-term symptoms like craving and withdrawal, not for staying in treatment, avoiding relapse, or achieving abstinence.

**Weigh the finding by the design behind it**Over 80% of the Beneficial short-term findings came from weaker study designs, not randomized controlled trials.

**Look at the sustained outcomes specifically**Retention, relapse, and abstinence were predominantly No Significant Effect, most clearly in opioid use disorder.

**Hold the authors’ own caveat**The study authors state directly that adequately powered, adjunctive randomized trials with biochemically verified endpoints are still needed.

The Research Question
Does cannabinoid exposure improve outcomes, both short-term symptoms and sustained treatment success, across opioid, alcohol, cocaine, tobacco, and methamphetamine use disorders?

The Patient Question
Could using cannabis or a cannabinoid product help me stay off opioids, alcohol, or another substance long-term, or is any benefit limited to short-term symptom relief?

The Bottom Line
The evidence currently supports possible short-term symptom relief, mostly from weaker studies, but not sustained treatment success, and rigorous randomized trials are still needed to know whether cannabinoids genuinely help long-term recovery.

CED Perspective Lens

## The Same Study Can Mean Different Things Depending on the Question Being Asked

Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.

Lens Overview
Eight perspectives keep a review with a headline 45.6% Beneficial rate from being oversold as proof that cannabinoids treat addiction, or dismissed because more than half of findings showed no benefit.

#### Short-Term Relief Is Not the Same as Long-Term Success

If you are in treatment for a substance use disorder and considering cannabis or a cannabinoid product, this review found some support for short-term relief of craving, withdrawal, or consumption, but that support comes mostly from weaker studies.

It did not find good evidence that cannabinoids help you stay in treatment, avoid relapse, or reach lasting abstinence, the outcomes that matter most for long-term recovery.

Lens takeaway
Ask your treatment team before using cannabinoids as an addiction aid, and do not expect them to replace proven treatment.

#### A Useful Map of Where the Evidence Actually Stands

For clinicians treating substance use disorders, this review offers a rare, comprehensive look at where cannabinoid evidence is strong, weak, or simply absent across five major disorders, rather than relying on scattered single studies.

The strongest, most rigorously tested evidence sits in opioid use disorder, and even there, sustained outcomes were predominantly null. That should temper enthusiasm for cannabinoids as an adjunctive OUD treatment until better trials exist.

Lens takeaway
Useful for setting realistic expectations with patients, not for recommending cannabinoids as adjunctive SUD treatment yet.

#### The Headline Percentage Undersells the Weakness Beneath It

A 45.6% Beneficial rate sounds encouraging until you learn that the vast majority of those findings came from weaker, more bias-prone study designs, precisely the kind of evidence a tier-weighted review is meant to discount rather than celebrate.

The review’s own methodology is the best evidence against overselling it: when the authors weighted by design quality, the picture shifted decisively toward not demonstrated for the outcomes that matter most.

Lens takeaway
Read the tier-weighting, not just the topline percentage.

#### A Fair Answer to a Common Patient Question

Family physicians and primary care clinicians are often the first to field questions from patients in recovery about whether cannabis could help with cravings or withdrawal during treatment.

This review supports a specific, honest answer: possible short-term symptom relief with weak evidentiary support, and no current evidence for improving long-term treatment success.

Lens takeaway
A precise, evidence-based answer beats either blanket approval or blanket dismissal.

#### A Narrative Synthesis, Not a Meta-Analysis

This is a narrative synthesis using the SWiM framework, not a formal meta-analysis, so there is no pooled effect size or confidence interval quantifying how large or reliable any individual benefit is.

Classifying 195 endpoint instances into categories like Beneficial, Mixed/Partial, and Harmful/Inferior necessarily involves reviewer judgment, even when applied through a pre-registered, systematic process.

Lens takeaway
A rigorous synthesis with real methodological limits that keep its findings descriptive rather than quantitatively precise.

#### Symptom Relief Still Has Value, Even Without Proven Cure

Even if cannabinoids do not improve sustained treatment outcomes, short-term relief of craving or withdrawal discomfort can still matter to a person’s day-to-day experience of treatment, provided it is framed honestly rather than as a cure.

The review’s own data show that this symptom-level benefit is where the, still weak, evidence actually points, not toward relapse prevention or abstinence.

Lens takeaway
Symptom comfort is not nothing, but it should not be marketed as addiction treatment.

#### Precision Protects Patients in Recovery

Headlines simplifying this review into cannabis helps treat addiction would misrepresent a review whose sustained-outcome findings were predominantly null.

For a population already navigating a high-stakes, high-relapse-risk condition, accurate public communication about what the evidence does and does not show protects patients from false hope and undertested self-treatment.

Lens takeaway
Report the short-term-versus-sustained distinction accurately rather than collapsing it into a single verdict.

#### A Clear Case for the Trials That Have Not Been Run

The authors’ call for adequately powered, adjunctive randomized trials with biochemically verified endpoints is a direct, actionable research priority, not boilerplate language.

Given the scale of the opioid overdose crisis, funding rigorous trials to resolve whether cannabinoids have any real role in sustained OUD recovery is a reasonable use of research investment, precisely because this review shows the current evidence cannot answer that question.

Lens takeaway
This review makes the case for funding the randomized trials it says are still needed.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Share this Evidence Watch

[X](https://twitter.com/intent/tweet?text=Cannabinoids+for+Substance+Use+Disorders%3A+What+97+Studies+Show+and+Do+Not+Show&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-substance-use-disorders-review%2F)
[LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-substance-use-disorders-review%2F)
[BlueSky](https://bsky.app/intent/compose?text=Cannabinoids+for+Substance+Use+Disorders%3A+What+97+Studies+Show+and+Do+Not+Show%20https%3A%2F%2Fcedclinic.com%2Fcannabinoids-substance-use-disorders-review%2F)
[Instagram](https://www.instagram.com/drcaplan/)
[Substack](https://doctorapprovedcannabis.substack.com/)
[RSS](https://cedclinic.com/feed/)

Source: [Zammit Dimech D, Zammit Dimech AA, Grech L, Serracino Inglott A. Cannabinoid exposure across substance use disorders: Short-term symptom benefits without sustained therapeutic gains in a tier-weighted systematic review. Eur Psychiatry. 2026;69(1):e73. DOI: 10.1192/j.eurpsy.2026.12236. PMID: 42466639.](https://doi.org/10.1192/j.eurpsy.2026.12236)

Related Reading at CED Clinic
Continue exploring the evidence

[Are We Over-Diagnosing Cannabis Use Disorder in Prescribed Medical Cannabis Patients?](https://cedclinic.com/prescription-cannabis-use-disorder-dsm5-study/)

A CED review of an Addiction journal study questioning whether standard DSM-5 criteria fit prescribed medical cannabis patients, useful context for how [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) itself is measured in clinical populations.

[Read the CUD diagnosis review](https://cedclinic.com/prescription-cannabis-use-disorder-dsm5-study/)

[Cannabis and Cocaine Use During Treatment: What Urine Testing Found](https://cedclinic.com/cannabis-cocaine-use-treatment-urine-analysis/)
A CED look at a urine-testing analysis finding an association between THC-positive and cocaine-positive tests during treatment, directly relevant to the polysubstance-use populations covered in this broader cannabinoid-SUD review.

[Read the cocaine treatment analysis](https://cedclinic.com/cannabis-cocaine-use-treatment-urine-analysis/)

[Cannabis Use, Cannabis Use Disorder Are Not The Same](https://cedclinic.com/cannabis-use-and-cannabis-use-disorder-genetics/)
A CED review distinguishing cannabis use from [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) at the genetic level, useful background for understanding why this review treats SUD outcomes as a distinct, carefully defined category.

[Read the genetics review](https://cedclinic.com/cannabis-use-and-cannabis-use-disorder-genetics/)

## Frequently Asked Questions

What did this review look at?

A tier-weighted systematic review searched PubMed and Embase from 1975 to 2025 for human studies evaluating cannabinoid exposure in relation to substance use disorder outcomes, covering opioid, alcohol, cocaine, tobacco, and methamphetamine use disorders. It included 97 studies and 41,954 participants.

What outcomes did the review measure?

Six prespecified endpoints were mapped to each disorder: treatment retention, relapse, abstinence, craving, withdrawal severity, and consumption, covering both short-term symptom relief and the sustained outcomes that define successful addiction treatment.

What does tier-weighted mean in this review?

The review used a design-based weighting scheme, following Synthesis Without Meta-analysis (SWiM) guidance, that gave randomized controlled trials the highest weight (1.00) and qualitative studies the lowest weight (0.25), so findings from weaker study designs would not be counted the same as findings from rigorous trials.

How many findings were classified as Beneficial?

Of 195 endpoint instances across the 97 studies, 89 (45.6%) were classified as Beneficial, 80 (41.0%) as No Significant Effect, 12 (6.2%) as Mixed or Partial, and 14 (7.2%) as Harmful or Inferior.

Were the Beneficial findings for short-term symptoms or long-term recovery?

The large majority, 76.4%, of Beneficial findings were for short-term symptom targets such as craving, withdrawal, and consumption, not for treatment retention, relapse prevention, or abstinence.

How strong was the evidence behind those short-term Beneficial findings?

Weak. Beneficial findings for craving (81.5%), withdrawal severity (85.7%), and consumption (80.0%) came overwhelmingly from weaker study designs rather than from randomized controlled trials.

Did cannabinoids help people stay in treatment or avoid relapse?

Not according to this review. Sustained outcomes like treatment retention, relapse, and abstinence were predominantly classified as No Significant Effect, a pattern most pronounced in opioid use disorder, where the evidence base was largest and most rigorous.

Is this a meta-analysis?

No. This is a narrative synthesis using the Synthesis Without Meta-analysis (SWiM) framework, not a formal meta-analysis, so there is no pooled effect size or confidence interval quantifying the size of any individual benefit.

What do the study authors conclude?

The authors conclude that cannabinoids confer short-horizon symptomatic benefits but do not demonstrate efficacy for sustained abstinence, relapse prevention, or treatment retention, most clearly for opioid use disorder, and that adequately powered adjunctive randomized trials with biochemically verified endpoints are still needed.

What should someone in addiction treatment take away from this?

This review does not support using cannabinoids as a proven treatment for any substance use disorder. It suggests possible short-term symptom relief with weak evidentiary support, and no current evidence that cannabinoids improve the sustained outcomes that define successful long-term recovery. Anyone considering this should discuss it with their treatment team first.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).